Moderna, Inc. (NASDAQ:MRNA, &ldquo, Moderna&rdquo, )) and Immatics N.V. (NASDAQ:IMTX, &ldquo, Immatics&rdquo, )), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting
US 11648276 B2
Abstract
The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of
Immatics N.V. (NASDAQ: IMTX) shares are shooting higher today after it revealed an interim clinical data update for 11 patients with recurrent and/or refractory solid cancers treated with ACTengine IMA203 TCR-T monotherapy in the ongoing Phase 1b
U.S. stocks traded lower this morning even as the Federal Reserve’s two-day meeting began.
Following the market opening Tuesday, the Dow traded down 0.47% to 33,891.31 while the NASDAQ fell 0.12% to 12,197.84. The S&P 500 also declined, losing 0.37% to 4,152.34.